Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.0800 (-3.41%) ($7.0200 - $7.4000) on Fri. Aug. 2, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.91% (three month average) | RSI | 34 | Latest Price | $7.0800(-3.41%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.955% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-9%) IFRA(-7%) UUP(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.955% (StdDev 3.91%) | Hourly BBV | 0 () | Intraday Trend | -2.5% | | | |
|
1 - 5 Day Possible Target | $-2.42(-134.18%) | Resistance Level | $7.68 | 5 Day Moving Average | $7.39(-4.19%) | 10 Day Moving Average | $7.4(-4.32%) | 20 Day Moving Average | $7.68(-7.81%) | To recent high | -21.2% | To recent low | 12.9% | Market Cap | $897m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |